Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Pamvatamig

Generic Name: Pamvatamig

Overview

No overview information available.

Background

No background information available.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Study of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with AGA and MET Amplification.

Phase 2

Not yet recruiting

Posted: 2025/03/20

Sponsor:Betta Pharmaceutical...

ID:NCT06885840

Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors

Phase 1

Recruiting

Posted: 2021/06/18

Sponsor:Betta Pharmaceutical...

ID:NCT04930432

Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

Phase 1

Recruiting

Posted: 2021/05/03

Sponsor:Merus N.V.

ID:NCT04868877

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

Pipeline Analysis Reveals 20+ Drug Candidates for c-MET+ NSCLC Treatment

4 months ago

DelveInsight's latest pipeline report identifies over 20 pharmaceutical companies actively developing treatments for c-MET-positive Non-Small Cell Lung Cancer, with multiple promising candidates in various clinical stages.

Merus Advances Petosemtamab and Zenocutuzumab in Phase III Trials for Head and Neck Cancer and NRG1+ Cancers

7 months ago

Merus is actively enrolling patients in Phase III trials for petosemtamab, both as a first-line treatment in combination with pembrolizumab and as a monotherapy for second and third-line treatment of head and neck squamous cell carcinoma (HNSCC).

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy